Trending Stock News

Cobblestone Capital Advisors Lifted By $372,645 Its Southern Co (SO) Stake; Regenxbio (RGNX) Shorts Decreased By 6.18%

Cobblestone Capital Advisors Llc increased Southern Co (SO) stake by 108.47% reported in 2017Q3 SEC filing. Cobblestone Capital Advisors Llc acquired 7,605 shares as Southern Co (SO)’s stock rose 4.35%. The Cobblestone Capital Advisors Llc holds 14,616 shares with $718,000 value, up from 7,011 last quarter. Southern Co now has $44.09 billion valuation. The stock decreased 0.11% or $0.05 during the last trading session, reaching $43.93. About 7.86 million shares traded or 14.79% up from the average. The Southern Company (NYSE:SO) has risen 2.49% since February 18, 2017 and is uptrending. It has underperformed by 14.21% the S&P500.

Regenxbio Incorporated (NASDAQ:RGNX) had a decrease of 6.18% in short interest. RGNX’s SI was 1.24 million shares in February as released by FINRA. Its down 6.18% from 1.32 million shares previously. With 237,200 avg volume, 5 days are for Regenxbio Incorporated (NASDAQ:RGNX)’s short sellers to cover RGNX’s short positions. The SI to Regenxbio Incorporated’s float is 5.14%. The stock increased 0.19% or $0.05 during the last trading session, reaching $26.85. About 148,395 shares traded. Regenxbio Inc. (NASDAQ:RGNX) has risen 51.43% since February 18, 2017 and is uptrending. It has outperformed by 34.73% the S&P500.

Among 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Regenxbio had 4 analyst reports since October 12, 2015 according to SRatingsIntel. The rating was initiated by Chardan Capital Markets on Tuesday, October 20 with “Buy”. On Monday, October 12 the stock rating was initiated by Piper Jaffray with “Overweight”. Bank of America initiated the stock with “Buy” rating in Monday, October 12 report. As per Tuesday, October 13, the company rating was initiated by Morgan Stanley.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The company has market cap of $836.25 million. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. It currently has negative earnings. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.

Investors sentiment decreased to 1 in Q3 2017. Its down 0.16, from 1.16 in 2017Q2. It dived, as 51 investors sold SO shares while 353 reduced holdings. 76 funds opened positions while 330 raised stakes. 525.28 million shares or 0.91% more from 520.53 million shares in 2017Q2 were reported. Lathrop Invest Corporation reported 4,800 shares. Qci Asset Inc New York holds 191,051 shares. Truepoint reported 55,676 shares. Golub Group Inc Inc Ltd Company reported 0.03% stake. Cetera Advisors Ltd Liability Corporation reported 0.21% stake. Greenleaf invested in 0% or 922 shares. Baystate Wealth Mgmt Ltd Company accumulated 1,347 shares. Beaumont Fincl Ptnrs Limited Company owns 5,501 shares for 0.03% of their portfolio. Mitsubishi Ufj & Banking invested in 2.38M shares or 0.22% of the stock. Cambridge Investment Research Advsr Inc reported 0.14% in The Southern Company (NYSE:SO). Boston Limited Liability has invested 0.01% of its portfolio in The Southern Company (NYSE:SO). Cwm Limited Liability Company holds 0% or 1,654 shares in its portfolio. Pittenger And Anderson has invested 0% in The Southern Company (NYSE:SO). Credit Suisse Ag stated it has 0.06% of its portfolio in The Southern Company (NYSE:SO). Monroe Bank & Trust & Tru Mi invested in 0.04% or 2,330 shares.

Since October 10, 2017, it had 0 buys, and 4 sales for $8.29 million activity. The insider Daiss Ann P sold $261,400. BOWERS WILLIAM P had sold 85,151 shares worth $4.26 million. 25,000 shares were sold by Kerr – II James Y, worth $1.30M. Shares for $2.46M were sold by BEATTIE ART P on Thursday, October 26.

Among 20 analysts covering The Southern Company (NYSE:SO), 5 have Buy rating, 6 Sell and 9 Hold. Therefore 25% are positive. The Southern Company had 63 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Sector Perform” rating by Howard Weil given on Friday, May 13. The rating was maintained by Goldman Sachs on Thursday, July 14 with “Neutral”. As per Thursday, December 15, the company rating was initiated by Citigroup. On Thursday, January 11 the stock rating was downgraded by Goldman Sachs to “Sell”. The rating was maintained by BMO Capital Markets on Wednesday, August 2 with “Hold”. Zacks upgraded The Southern Company (NYSE:SO) on Sunday, August 16 to “Hold” rating. The firm has “Underweight” rating given on Thursday, August 10 by Morgan Stanley. SunTrust maintained the stock with “Hold” rating in Tuesday, January 16 report. The firm earned “Neutral” rating on Monday, October 19 by SunTrust. The stock of The Southern Company (NYSE:SO) has “Buy” rating given on Tuesday, June 6 by Jefferies.

Cobblestone Capital Advisors Llc decreased Ishares Edge Msci Usa Momentum (MTUM) stake by 5,731 shares to 128,235 valued at $12.27 million in 2017Q3. It also reduced Vanguard Extended Mkt Etf (VXF) stake by 4,315 shares and now owns 346,107 shares. Berkshire Hathaway Cl A (BRKA) was reduced too.

Leave a Reply

Your email address will not be published. Required fields are marked *